ERBB2 and breast cancer: However, the technological complexity and high operating costs have limited its use in the clinic, leading to the development of immunohistochemistry (IHC)-based surrogates for identifying intrinsic subtypes of breast cancer (luminal A, luminal B, HER2-enriched, basal-like, and normal-like [6, 7].